Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2003-06-18
2009-12-01
Yu, Misook (Department: 1642)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07625860
ABSTRACT:
Methods and compositions for modulating the FGF effect on the sensitivity of malignant and normal cells to anticancer agents are provided. In particular, methods and compositions for inhibiting FGF-induced resistance to a broad spectrum of anticancer agents in solid and soft-tissue tumors, metastatic lesions, leukemia and lymphoma are provided. Preferably, the compositions include at least one FGF inhibitor in combination with a cytotoxic agents, e.g., antimicrotubule agents, topoisomerase I inhibitors, topoisomerase II inhibitors, antimetabolites, mitotic inhibitors, alkylating agents, intercalating agents, agents capable of interfering with a signal transduction pathway (e.g., g., a protein kinase C inhibitor, e.g., an anti-hormone, e.g., an antibody against growth factor receptors), an agent that promotes apoptosis and/or necrosis, an interferon, an interleukin, a tumor necrosis factor, and radiation.In other embodiments, methods and composition for protecting a cell in a subject, from one or more of killing, inhibition of growth or division or other damage caused, e.g., by a cytotoxic agent, are provided. Preferably, the method includes: administering, to the subject, an effective amount of at least one FGF agonist, thereby treating the cell, e.g., protecting or reducing the damage to the dividing cell from said cytotoxic agent.
REFERENCES:
Barry, W, Nature Biotechnology 22, 165-167 (2004).
Miller, S 2002, J Invest Dermatol, vol. 118, pp. 216-225.
Iliakis et al., May 1989;16(5):1261-5, abstract only.
Katsuoka et al., Arch Dermatol Res. 1987;279(4):247-50.
Ozeki et al., (Tissue Engineering, vol. 8, 2002, pp. 359-366).
Jimenez, J., et al.,“Protection From 1-β-D-Arabinoturanosyleytosine-Induced Alopecia by Epidermal Growth Factor and Fibroblast Growth Factor in the Rat Model”, Cancer Research, 52, 413-415(1992).
Gao, Xiang, et al., “Use of Drug Kinetics in Dermis to Predict in Vivo Blood Concentration After Topical Application”, Phar. Research, vol. 12, No. 1 (1995).
Gupta, Elora, et al., “Penetration Kinetics of 2′, 3′-Dideoxyinosine in Dermis is described by the Distributed Model”, Phar. Research, vol. 12, No. 1 (1995).
Mukherji, E., et al., “Percutaneous Absorption of 2′, 3′-Dideoxyinosine in Rats”, Phar. Research, vol. 11, No. 6 (1994).
Wang, J., et al., “Protection Against Chemotherapy-Induced Alopecia”, Phar. Research, vol. 23, No. 11, (2006).
Bertolotto, C, Maulon, L, Filippa, N. et al., Protein kinase C theta and epsilon promote T-cell survival by a rsk-dependent phosphorylation and inactivation of BAD. J. Biol. Chem., yr 2000, pp. 37246-37250, vol. 275.
Bonni, A, Brunet, A, Eest, AE et al., Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science, yr 1999, pp. 1358-1362, vol. 286.
Burgess, WH, and Maciag, T, The heparin-binding (flibroblast) growth factor family of proteins. Ann. Rev. Biochem., yr 1989, pp. 575-606, vol. 58.
Cardone, MH, Roy, N, Stennicke, HR et al., Regulation of cell death protease caspase-9 by phosphorylation. Science, yr 1998, pp. 1318-1321, vol. 282.
Carmean, N, Kosman, JW, Leaf, EM et al., Immortalization of human urothelial cells by human papillomavirus type 16 E6 and E7 genes in a defined serum-free system. Cell Prolif., yr 2007, pp. 166-184, vol. 40.
Chen, C, Edelstein, LC, and Gelinas, C, The Rel/NF-kB Family Directly Activates Expression of the Apoptosis Inhibitor Bcl-xL. Molec. Cell. Biol., yr 2000, pp. 2687-2695, vol. 20.
Delehedde, M, Seve, M, Sergeant, N, et al., Fibroblast growth factor-2 stimulation of p42/44MAPK phosphorylation and IkappaB degradation is regulated by heparan sulfate/heparin in rat mammary fibroblasts. j.Biol. Chem., yr 2000 pp. 33905-33910, vol. 275.
Dell'Era, P. Mohammadi, M, and Presta, M, Different tyrosine autophosphorylation requirements in fibroblast growth factor receptor-1 mediated ukokinase-type plasminogen activator induction and mitogenesis, Molec. Biol. Cell., yr 1999, pp. 23-33, vol. 10.
Devita, VT, Jr., Principles of cancer management: chemotherapy. In: DeVita, V,T,, Hellman,S., Rosengerg,S.A. (eds.) Cancer, principles and practice of oncology, pp. 333-347. Philidelphia: Lippincott-Raven, 1997.
Du, K, and Montiminy, M, Creb is a regulatory target for the protein kinase Akt/PKB. j. Biol Chem., yr 1998, pp. 32337-32379, vol. 273.
Friesel, RE, and Maciag, T, Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction, FASEB J., yr 1995, pp. 919-925, vol. 9.
Ghoda, L, Lin, X and Greene, WC, The 90-kDa ribosomal S6 kinase (pp90rsk) phosphorylates the N-terminal regulatory domain of IkappaBalpha and stimulates its degradation in vitro. J. Biol. Chem., yr 1997, pp. 21281-21288, vol. 272.
Gospodarowicz, D, Cheng, J, Lui, GM, et al., Isolation of brain fibroblast growth factor by heparin-Sepharose affinity chromatography: identity with pituitary fibroblast growth factor. Proc. Natl. Acad. Sci. U.S.A. yr 1984, pp. 6963-6967, vol. 81.
Hayashi, I, Nixon, T, Morikawa, M, et al., Adipogenic and anti-adipogenic factors in the pituitary and other organs. Proc. Natl. Acad. Sci. U.S.A., yr 1981, pp. 3969-3972, vol. 78.
Hellman, S. Principles of cancer management: raiation therapy. In: DeVita, V.T., Hellman, S., Rosengery, S.A. (eds), Cancer, principles and practice of oncology, pp. 307-332. Philidelphia: Lippincott-Raven, 1997.
Kent, KD, and Bomser, JA, Bovine pituitary extract provides remarkable protection against oxidative stress in human prostate epithelial cells. In Vitro Cell Dev. Biol. Anim, yr 2003, pp. 388-394, vol. 39.
Miho, Y, Kouroku, Y, Fujita, E, et al., bFGF inhibits the activation of caspase-3 and apoptosis of P19 embryonal carcinoma cells during neuronal differentiation. Cell Death Differ., yr 1999, pp. 463-470, vol. 6.
Ornitz, DM, Xu, J, Colvin. JS, et al., Receptor specificity of the fibroblast growth factor family, J. Biol. Chem., yr 1996, pp. 15292-15297, vol. 271.
Ozeki, M, and Tabata, Y, Promoted growth of murine hair follicles through controlled release of basic fibroblast growth factor. Tissue Eng, yr 2002, pp. 359-366, vol. 8.
Pollock, GS, Franceschini, IA, Graham, G et al., Neuregulin is a mitogen and survival factor for olfactory bulb ensheathing cells and an isoform is produced by astrocytes, Eur. J. Neurrosci., yr 1999, pp. 769-780, vol. 11.
Powers, CJ, Mcleskey, SW, and Wellstein, A, Fibroblast growth factors, their receptors and signaling, Endocrine-Related Cancer, ry 2000, pp. 165-167, vol. 7.
Shimamura, A, Ballif, BA, Richards, SA, et al., Rsk1 mediates a MEK-MAP kinase cell survival signal. Curr. Biol., yr 2000, pp. 127-135, vol. 10.
Spivak-Kroizman, T, Lemmon, MA, Dikic I, et al., Heparin-induced oligomerization of FGF modules is responsible for FGF receptor dimerization, activation and cell proliferation. Cell, yr 1994, pp. 1015-1-24, vol. 79.
Tan. Y, Ruan, H, Demeter, MR, et al., p90(RSK) blocks bad-mediated cell death via a protein kinase C-dependent pathway. J. Biol. Chem., yr 1999, pp. 34867, vol. 274.
Wang, J, Lu, Z and Au, JL, Protection Against Chemotheray-Induced Alopecia, Pharm. Res, yr 2006, pp. 2505-2514, vol. 23.
Wert, MM, and Palfrey, HC, Divergence in the anti-apoptotic signalling pathways used by nerve growth factor and basic fibroblast growth factor (bFGF) in PC12 cells: rescue by bFGF involved protein kinase C delta. Biochem. J., yr 2000, pp. 175-182. vol. 352.
Xing, J, Ginty, DD and Greenberg, ME, Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase, Science, yr 1996, pp. 9595-9563, vol. 73.
Zong, WX, Edelstein, LC, Chen, C, et al., The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kB that blocks TNFa-induced apoptosis. Genes & Development, yr 1999, pp. 382-387, vol. 13.
Au Jessie L.-S.
Wientjes M. Guillaume
Mueller Smith & Okuley, LLC
Yu Misook
LandOfFree
Methods and compositions for modulating cell proliferation... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for modulating cell proliferation..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for modulating cell proliferation... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4124533